The company's average rating is Strong Buy from 2 analysts.
We provide advice to complement the current
expert consensus on Stereotaxis. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Stereotaxis? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Stereotaxis this year
Annual and quarterly reports issued by Stereotaxis are formal
financial statements that are published yearly and quarterly and sent to Stereotaxis stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Stereotaxis often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is Stereotaxis a risky opportunity?
Let's check the volatility. Stereotaxis is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Stereotaxis (AMEX:STXS) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. buying a share of a Stereotaxis stock makes you a part-owner of that company.
Stereotaxis Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Stereotaxis. The Stereotaxis consensus assessment is calculated by taking the average estimates from all of the analysts covering Stereotaxis
| Strong Buy | 2 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Our perspective of the latest Stereotaxis spike
Latest downside deviation is at 3.91.
As of the 9th of May, Stereotaxis has the Risk Adjusted Performance of 0.0971,
semi deviation of 3.22, and Coefficient Of Variation of 821.96. In relation to
fundamental indicators, the
technical analysis model makes it possible for you to check existing technical drivers of Stereotaxis, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have analyzed and interpolated nineteen
technical drivers for Stereotaxis, which can be compared to its competition. Please validate
Stereotaxis semi deviation,
jensen alpha, as well as the
relationship between the Jensen Alpha and
semi variance to decide if Stereotaxis is priced more or less accurately, providing market reflects its prevalent price of 6.7 per share. Given that Stereotaxis has
jensen alpha of 1.03, we advise you to double-check Stereotaxis's current market performance to make sure the company can sustain itself at a future point.
Our Takeaway on Stereotaxis Investment
While some firms under the medical instruments & supplies industry are still a bit expensive, Stereotaxis may offer a potential longer-term growth to retail investors. Taking everything into account, as of the 9th of May 2021, our research shows that Stereotaxis is a rather moderately volatile investment opportunity with a
very small probability of distress in the next two years. From a slightly different view, the entity currently appears to be
undervalued. However, our up-to-date 90 days recommendation on the enterprise is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Stereotaxis. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
